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Abstract 
The acetylcholine receptor-operated K+ (KACh) channel may be a novel target for 
atrial-specific antiarrhythmic therapy. Recently it has been demonstrated that tertiapin, a 
selective blocker of KACh channel, suppressed aconitine-induced atrial fibrillation (AF) in 
dogs. However, precise mechanism by which the KACh channel blocker inhibits the 
aconitine-induced AF remains unknown. This study was undertaken to determine the role of 
KACh channel in aconitine-induced AF in guinea pigs. Tertiapin terminated the 
aconitine-induced AF in anesthetized guinea pigs. The results of in vitro electrophysiological 
experiment using atrial cells and atrial preparations suggest that aconitine might activate KACh 
channel in atrial cells, probably by intracellular Na+ accumulation, and inhibition of KACh 
channel by tertiapin might suppress AF by producing conduction block, probably due to 
further decrease in the resting membrane potential. Since it has been reported that 
constitutively active KACh channels can be observed in atrial cells of patients with chronic AF, 
aconitine-induced AF may be used as an experimental model for evaluation of drug effect on 
chronic AF.  
 
 
Key words: acetylcholine receptor-operated K+ channel, atrial fibrillation, aconitine, 
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1. Introduction 
Aconitine, a poisonous alkaloid known as an arrhythmogenic compound, activates Na+ 
channels with inactivation slowing, and produces intracellular Na+ accumulation in cardiac 
cells (1-3). The alkaloid has long been used to produce experimental atrial fibrillation (AF) 
probably due to induction of abnormal automaticity.  
Recently much attention has been focused on the acetylcholine receptor-operated K+  
(KACh) channel as a novel target of pharmacotherapy for atrial fibrillation because activation 
of KACh channel may play an important role in the induction of parasympathetic-type atrial 
fibrillation occurring at night, at rest and/or after consuming meals or alcohol (4).  Several 
atria-selective antiarrhythmic drugs blocking KACh channels, such as NIP-151 and NTC-801, 
have been developed (5, 6). It has been demonstrated that not only these atria-selective 
antiarrhythmic drugs but also tertiapine, a bee venom peptide specifically inhibiting KACh 
current (IK.ACh) without affecting other membrane currents (7-9), can effectively terminate 
aconitine-induced AF in dogs (6, 10). However, precise mechanism by which these KACh 
channel blockers inhibit aconitine-induced AF model remains unknown. Therefore, this study 
was undertaken to explore the mechanism by which the specific KACh channel blocker 
tertiapine inhibits the aconitine-induced AF.  
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Material and methods 
All experiments were performed under the regulations of the Animal Research 
Committee of Chiba University Graduate School of Medicine.  
 
In vivo experiments 
Guinea pigs weighing 250 – 450 g were anesthetized with pentobarbital sodium (30 
mg/kg, i.p.). They were ventilated with room air through an endotracheal tube inserted to 
trachea using an artificial ventilator (SN-480-7, Shinano Manufacturing Co., Tokyo, Japan). 
The surface lead II ECG was recorded using limb electrodes.  The chest was opened and the 
heart was exposed. AF was induced by a topical application of aconitine (aconitine in saline 
solution with 5 % dimethyl sulfoxide at a concentration of 258 µg /ml) on the right appendage. 
Tertiapin (100 µg / kg) or pilsicainide (3 mg / kg) was administered through femoral vein as a 
bolus injection and then the incidence of AF termination rate was evaluated. 
 
Cell preparations 
Single atrial cells of the guinea-pig heart were isolated by an enzymatic dissociation 
method, as previously described (11).  The heart was removed from guinea pigs (body 
weight 250 – 400 g) anesthetized with pentobarbital sodium. Hearts were mounted on a 
Langendorff apparatus immediately after excision of the heart followed by cannulation of the 
aorta. The hearts were perfused at a constant pressure of 80 mmHg with warm (37°C) and 
oxygenated buffer solution. The heart was perfused sequentially with the following buffers: 1) 
normal HEPES-Tyrode solution for 10 min, 2) nominally Ca2+-free Tyrode solution for 10 
min, and 3) Ca2+-free Tyrode solution containing 0.1 – 0.2 mg/ml collagenase (Wako, Osaka, 
Japan) for 20 – 30 min. After digestion, the heart was perfused with a high-K+ low-Cl− 
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solution [modified Kraft-Brühe (KB) solution]. Atrial tissue was minced in the modified KB 
solution, and the pieces were gently agitated to dissociate cells. The cell suspension was 
stored at 4°C until use. 
 
Whole-cell patch clamp experiments 
The whole-cell patch-clamp techniques were used for the recordings of membrane 
currents and action potentials from single atrial cells. A patch-clamp amplifier (CEZ-2400, 
Nihon Kohden, Tokyo, Japan) was used for current- and voltage-clamp experiments. Pipette 
electrodes (resistance 4–6 MΩ) were made by using a Narishige pipette puller (PB-7, 
Narishige Scientific Instruments Laboratory, Tokyo, Japan). After the gigaohm seal between 
tip and cell membrane was formed, we ruptured the patch membrane to form the whole-cell 
patch clamp configuration. In the current-clamp mode, action potentials were evoked by 
stimulation of the atrial cell at an interval of 5 s. In the voltage-clamp mode, a ramp-pulse 
protocol was used to record the quasi-steady-state membrane current at an interval of 20 s. 
The membrane potential was held at −40 mV and depolarized to +50 mV in 150 ms. It was 
then repolarized or hyperpolarized to −100 mV in 250 ms, during which time the change in 
the membrane current was automatically plotted against the membrane potential.  
The experiments were performed at 36°C. The current signals were filtered at 10 
kHz and digitalized at 1 or 2 kHz by using an A/D converter (Digidata 1322A, Axon 
Instruments Inc., Union City, CA, USA). All data were stored on a computer for later analysis 
with pCLAMP9 software (Axon Instruments).  
 
1.1.  Two dimensional electrical mapping 
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The 64-channel multi-electrode dish system (MED64, Alpha MED Scientific Inc., 
Osaka, Japan) was used for two dimensional electrical mapping. The system was equipped 
with MED-P545A probes with 450 µm interpolar distance of electrodes, a chamber with 
depth of 10 mm and 64 planar microelectrodes in an 8 × 8 array for determination of the 
propagation patterns in atrial preparations. Atrial appendages were obtained from anesthetized 
guinea pigs and washed with Krebs-Henseleit solution. The experiments were performed at 
36°C. Atrial preparations were superfused with oxygenated Krebs-Henseleit solution and 
electrically stimulated at 0.5 Hz. Data obtained with this system were analyzed using the 
software (MED64 conductor for evaluation) and custom-made macros in Excel (Microsoft, 
Redmont, WA, U.S.A.). Experimental groups were composed of preparations exposed to 3 
µM aconitine alone (n = 5), 3 µM aconitine followed by addition of 30 nM tertiapine (n = 6) 
and 3 µM aconitine followed by addition of 10 µM pilsicainide (n = 5). Conduction velocity 
was calculated from electrical mapping data at several time points in each experiment. 
 
1.2.  Solutions 
The compositions of the buffers used in the experiments are as follows: 1) Normal 
HEPES-Tyrode solution (in mM): NaCl 143, KCl 5.4, CaCl2 1.8, MgCl2 0.5, NaH2PO4 0.33, 
glucose 5.5, and HEPES-NaOH buffer 5 (pH 7.4) ; 2) KB solution (in mM): KOH 70, 
L-glutamic acid 50, KCl 40, taurine 20, KH2PO4 20, MgCl2 3, glucose 10, EGTA 1, and 
HEPES-KOH buffer 10 (pH 7.4) ; 3) The pipette solution for ruptured patch experiments (in 
mM): KOH 110, L-aspartic acid 110, KCl 20, MgCl2 1, CaCl2 1.42, ATP-K2 5, potassium 
phosphocreatine 5, EGTA 10, GTP-Na3 0.1 and HEPES-KOH buffer 5 (pH 7.4) ; 4) 
Krebs-Henseleit solution (in mM): NaCl 119 , KCl 4.8, KH2PO4 1.2, MgSO4 1.2, CaCl2 2.5, 
glucose 10, NaHCO3 24.9 (saturated with 95% O2 + 5% CO2).  
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1.3.  Drugs 
The following drugs were used: aconitine (Sigma Chemical, St Louis, MO, U.S.A.), 
tertiapin (Peptide Institute, Inc, Osaka, Japan), pilsicainide (Daiichi Sankyo Pharmaceutical 
Co., Tokyo, Japan), carbachol chloride (Sigma Chemical, St Louis, MO, U.S.A.). Aconitine 
was dissolved in dimethylsulfoxide at a concentration 83.33mmol/L and diluted to 400 µM 
with saline for in vivo experiments. Aconitine was dissolved in absolute ethanol at a 
concentration of 10 mM/L and diluted to 3 µM for in vitro experiments. Tertiapin and 
pilsicainide was dissolved in distilled water. 
 
1.4. Statistics 
Data are expressed as mean + S.E. Statistical comparisons were made using Student’s 
t-test or analysis of variance combined with Fisher’s post hoc test, as appropriate. A value of 
p<0.05 was regarded as significant. 
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Results 
In vivo experiments evaluating drug effects on aconitine-induced AF 
Topical application of aconitine on the right atrium induced AF in anesthetized guinea 
pigs (Figure 1B and 1E). After induction of AF tertiapin (100 µg / kg) was intravenously 
administered to the guinea pig via femoral vein. Injection of tertiapin immediately converted 
the aconitine-induced AF to sinus rhythm, as shown in Figure 1C. Administration of 
pilsicainide (3 mg / kg), a class Ic antiarrhythmic drug, also terminated the aconitine-induced 
AF (Figure 1F). Success rates of AF termination with tertiapin (100 µg / kg) and pilsicainide 
(3 mg / kg) were 6/7 and 4/8, respectively.  It was reported that pilsicainide showed efficacy 
in canine arrhythmia models at the effective serum concentrations ranging from 0.25 µM to 
8.0 µM (12).  Pilsicainide at this concentration range was reported to hardly block either the 
muscarinic ACh receptors or the KACh channels (13) 
 
Effect of tertiapin on the action potential shortening induced by aconitine 
Effects of aconitine on the action potentials were examined in single atrial cells of 
guinea pigs. Action potentials were recorded in the current-clamp mode of patch clamp 
techniques. Application of 30 nM tertiapin slightly increased action potential duration (APD) 
in guinea pig atrial cells (Figure 2A) although an increase in APD90 (APD at 90% 
repolarization level) after tertiapin alone (from 94.0 ± 5.8 ms to 98.8 ± 5.5 ms, n=6) was 
statistically insignificant (Figure 2D).  Then we examined the effects of tertiapin on APD of 
atrial cells in the presence of aconitine.  Aconitine at a concentration of 3 µM slightly 
shortened APD (Figure 2B and 2D). Addition of 30 nM tertiapin reversed the APD shortening 
in the presence of aconitine in its early stage (Figure 2B). Aconitine at a concentration of 3 
µM decreased the APD90 (APD at 90% repolarization level) from 81.6 ± 5.7ms to 73.4 ± 4.5 
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ms, and addition of 30 nM tertiapin increased the APD90 to 106.5 ± 9.6 ms (n=7, p<0.01) 
(Figure 2D). In order to compare the effect of aconitine with that of carbachol, effects of 
tertiapin on the carbachol-induced action potential changes were examined. Carbachl at a 
concentration of 3 nM shortened APD in atrial cells, which was readily antagonized by 30 nM 
tertiapin (Figure 2C). APD90 was changed from 86.3 ± 11.2 ms to 63.3 ± 10.9 ms after 3 nM 
carbacol and it was increased to 96.4 ± 19.6 ms after addition of 30 nM tertiapin  (n=5) 
(Figure 2D). Thus, both carbachol and tertiapine shortened atrial action potential and the 
action potential shortening was antagonized by the KACh channel blocker tertiapin.  
 
Tertiapin-sensitive current induced by aconitine and carbachol 
The quasi-steady-state membrane current was recorded in the voltage-clamp mode 
using a ramp-pulse protocol. Addition of 30 nM tertiapin very slightly decreased the 
steady-state outward current (Figure 3A). Aconitine at a concentration of 3 µM slightly 
enhanced the steady-state outward current, and addition of 30 nM tertiapin reduced the 
steady-state membrane current enhanced by aconitine, as shown in Figure 3B. Carbachol at a 
concentration of 3 nM definitely increased the steady-state outward current, which was 
antagonized by 30 nM tertiapin (Figure 3C).  
We measured the tertiapin-sensitive current at 0 mV. Since tertiapin is known to 
selectively inhibit IK.ACh without any appreciable effect on other major ionic currents (IKr, IKs, 
Ito, IK1, IKATP, INa, and ICaL)(9), the tertiapin-sensitive current would be designated as IK.ACh. 
Tertiapin-sensitive current at 0 mV in the absence of any drug was very small (Figure 3D). 
The tertiapin-sensitive current at 0 mV in the presence of 3 µM aconitine (0.65 ± 0.10 pA/pF, 
n=10) was slightly and insignificantly larger than that in the absence of any drug (0.29 ± 0.13 
pA/pF, n=13). Carbachol (3 nM) produced a significantly greater increase of 
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tertiapin-sensitive current (2.43 ± 0.77 pA/pF, n=5) than that induced by aconitine (Figure 
3D).  
 
Changes of membrane potentials after longer exposure to aconitine in atrial cells 
Membrane potentials of isolated atrial cells were measured in the current-clamp mode. 
When atrial cells were exposed to 3 µM aconitine for a longer time, abnormal automaticity 
appeared and then 30 nM tertiapin was added to the external solution. Immediately after 
introduction of 3 µM aconitine the APD was shortened, and a few minutes later abnormal 
automaticity appeared, as shown in Figure 4A. After induction of abnormal automaticity 30 
nM tertiapin was added to the external solution and tertiapin markedly decreased the resting 
membrane potentials (Figure 4A). Figure 4B summarizes the changes of the resting 
membrane potential at the times when the abnormal automaticity was induced by aconitine, 
and when tertiapin was added to the external solution.  Aconitine per se slightly decreased 
the resting membrane potentials from -78.6 ± 1.0 mV to -70.9 ± 5.3 mV, and addition of 
tertiapin further decreased it to -40.2 ± 3.6 mV (p<0.01, n = 7). 
 
In vitro two dimensional electrical mapping in isolated atrial preparations 
We conducted the in vitro two dimensional electrical mapping experiments using 
atrial preparations of guinea pigs with MED64 multi-electrode array system. Electrical 
stimulation and recording of field potentials in isolated atrial tissues were conducted with 
MED64 system. Atrial preparations were placed directly on a grid of 64 planar 
microelectrodes, which serve a dual purpose of stimulus-delivery and signal recording. The 
time of signal peaks were recorded and plotted. In the mapping experiments, one color 
represented the time of signal peaks within 2 ms.  
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Firstly we started the electrical stimulation from some 2 adjacent electrodes in the 
atrial tissue placed on the probe. When we applied 3 µM aconitine to the preparation, the 
ectopic firing was induced.  At 15 min after introduction of aconitine, we added 30 nM 
tertiapin or 10 µM pilsicainide to the aconitine-containing solution. Aconitine induced ectopic 
firing with slowed conduction, as observed in the two dimensional electrical mapping of atrial 
preparations (Figure 5D, E, F). Addition of tertiapin further decreased the conduction velocity 
in preparations with combined treatment (Figure 5H), compared to the preparation treated 
with aconitine alone (Figure 5G). In a similar fashion addition of 10 µM pilsicainide further 
decreased the conduction velocity (Figure 5I). These drugs sometimes produced a collision of 
excitation waves. Thus either tertiapin or pilsicainide can decrease the conduction velocity, 
thereby producing conduction block. 
Conduction velocity was calculated from mapping data obtained during control period, 
at 15 min after introduction of 3 µM aconitine and at 5 min after addition of no drug, 30 nM 
tertiapin or 10 µM pilsicainide.  In aconitine alone group the conduction velocity gradually 
decreased from 0.26 ± 0.03 m/sec to 0.20 ± 0.03 m/sec at 15 min (Figure 6A). At 20 min after 
introduction of aconitine the conduction velocity further decreased to 0.16 ± 0.03 m/sec, 
which was statistically insignificant from the conduction velocity at 15 min. In tertiapin group, 
the conduction velocity decreased from 0.22 ± 0.04 m/sec to 0.19 ± 0.02 m/sec after 15-min 
exposure to 3 µM aconitine, and then significantly decreased to 0.06 ± 0.02 m/sec after 
addition of 30 nM tertiapin (p<0.05, n=6)(Figure 6B). In pilsicainide group, the conduction 
velocity significantly decreased from 0.16 ± 0.02 m/sec to 0.07 ± 0.02 m/sec after addition of 
10 µM pilisicainide (p<0.05, n=5)(Figure 6C). Thus, aconitine per se gradually decreased the 
conduction velocity in isolated atrial preparations and addition of tertiapin or pilsicainide 
significantly potentiated conduction slowing. 
                                                              
 12 
Discussion 
It is assumed that paroxysmal AF occurring at night, at rest, and/or after consuming 
meals or alcohol is caused by the activation of KACh channels (4). It is acknowledged that 
vagal nerve stimulation (VNS) shortens the atrial effective refractory period (ERP) and 
increases the heterogeneity via the activation of IK.ACh, which can facilitate the onset of AF. 
Recently it has been reported that NTC-801, a selective KACh channel blocker, effectively 
terminated VNS-induced AF in dogs (6). It is not surprising that the KACh channel blocker 
readily inhibited the VNS-induced AF. However, the KACh channel blocker could also inhibit 
aconitine-induced AF in dogs (6). The effectiveness of the KACh channel blocker against 
aconitine-induced AF cannot be readily explained. 
Aconitine has long been known as an arrhythmogenic compound. Aconitine is 
assumed to inhibit voltage-dependent Na+ channel inactivation and causes intracellular Na+ 
accumulation, resulting in intracellular Ca2+ accumulation and abnormal automaticity such as 
delayed afterdepolarizations and triggered activity (14).  Ectopic activity resulting from 
abnormal automaticity may trigger atrial fibrillation by reentrant mechanism.  It has been 
suggested that aconitine may bind to site 2 receptor Na+ channel and local anesthetics may 
noncompetitively inhibit the site 2 binding of plant alkaloid toxin (15). Aconitine was 
reported to induce early afterdepolarization, delayed afterdepolarization and triggered activity 
in isolated cardiomyocytes and cardiac tissues (16, 17). Consistent with the reports, we could 
observe abnormal automaticity in guinea-pig atrial cells after application of aconitine. 
The cardiac KACh channel plays an important role in the regulation of sinoatrial node 
automaticity and atrial action potential duration. The KACh channel is directly affected by βγ 
subunits of heterotrimeric GTP-binding (G) protein (18). In addition, the KACh channel is 
regulated by Na+ ions as well as phosphatidylinositol-bis-phosphate (PIP2)(19, 20). 
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Intracellular sodium ions exert their gating effects independently of the activation by the Gβγ 
subunits in the presence of PIP2 (20, 21). We hypothesized that accumulation of the 
intracellular sodium ions, produced by aconitine, might activate KAch channels in guinea-pig 
atrial cells.  
In order to test this hypothesis we conducted electrophysiological experiments. 
Aconitine slightly shortened action potential duration (APD) at its early stage, and addition of 
tertiapin reversed the APD shortening (Figure 2). We could observe a tertiapin-sensitive 
current after application of aconitine, which was slightly larger than that observed without 
aconitine treatment (Figure 3), although the muscarinic agonist carbachol produced more 
definite APD shortening and larger tertiapin-sensitive current. Aconitine might activate KACh 
current by intracellular Na+ accumulation. When atrial cells were exposed to aconitine for a 
longer time, spontaneous activity appeared (Figure 4). With addition of tertiapin, the resting 
membrane potential was marked reduced. Some inward current, resulting from Na+ current 
with slowed inactivation and intracellular Na+/Ca2+ accumulation, might play an important 
role in the marked depolarization of the resting membrane.  Activated KACh channels might 
contribute to keeping the resting membrane potential toward more hyperpolarizing direction. 
With KACh channel blockade marked membrane depolarization due to increased inward 
current might become overt. 
We conducted the in vitro two dimensional electrical mapping experiments using 
atrial preparations of guinea pigs. Aconitine induced ectopic firing in atrial preparations and 
gradually produced conduction slowing. Addition of tertiapin or pilsicainide further decreased 
the conduction velocity in the preparations pretreated with aconitine, which was more marked 
compared to that observed in the preparation treated with aconitine alone. Either tertiapin or 
pilsicainide might decrease the conduction velocity, thereby producing conduction block. 
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Inhibition of IK.ACh and reduction of the resting membrane potential by tertiapin in the 
presence of aconitine might play an important role in conduction slowing and resultant 
termination of AF. It is well known that the availability of sodium current, INa, decreases as 
the resting membrane potential depolarizes, resulting in a decrease of conduction velocity in 
cardiac tissues (22-24). Therefore, tertiapin might produce conduction block in reentrant 
pathway and/or propagation pathway from ectopic focus with abnormal automaticicty. 
Pilsicainide might similarly terminate the aconitine-inducced AF by producing conduction 
block. In this context it has been recently reported that pilsicainide decreased the conduction 
velocity in the left atrium as well as pulmonary vein of guinea pigs (25).  
It is well known that rapid atrial pacing produces electrical remodeling in the atrium, 
an arrhythmogenic substrate, and easily induces AF with a burst of atrial stimulation (26, 27). 
It is acknowledged that the densities of several membrane currents such as the L-type Ca2+ 
current (ICa-L) and transient outward current (Ito ) are reduced in remodeled atrial cells. It has 
been recently reported that atrial tachypacing in dogs produces electrical remodeling in which 
the density of the IK.ACh in atrial cells increases, even in the absence of a muscarinic agonist 
(28). Furthermore, IK.ACh is constitutively active in atrial cardiomyocytes from patients with 
long-term AF (29). Intracellular Na+ accumulation with repetitive atrial excitation in chronic 
AF might activate KACh channels in atrial cells even without muscarinic receptor stimulation. 
The results of the present study suggest that the aconitine-induced AF model can be a model 
of chronic AF since the activated KACh channels play an important role in the development 
and maintenance of experimental AF (28).  
In conclusion, IK.ACh plays an important role in the development and maintenance of 
experimental AF induced by aconitine and the KACh channel blocker can terminate the AF by 
decreasing the conduction velocity with reduction of the resting membrane potential. The 
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aconitine-induced AF may be a useful model to search for an effective drug to treat chronic 
AF.  
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Figure'1.'Termina(on*of'aconi(ne-induced*AF*by*ter(apin*and*pilsicainide*in*
anesthe(zed*guinea*pigs.**(A),*(D)*Representa(ve*surface*ECG*(lead*II)*showing*
normal*sinus*rhythm*during*control*period.*(B),*(E)*ECG*showing*AF*induced*by*a*
topical*applica(on*of*aconi(ne*(with*a*coHon*soaked*in*400*μM*coni(ne*solu(on)*
on*the*right*appendage.*(C)*ECG*recorded*aNer*a*bolus*injec(on*of*ter(apin*
(100μg/kg,*i.v.)*or*(F)*pilsicainide*(3*mg/kg,*i.v),*showing*termina(on*of*AF.
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Figure 2.  Effect of tertiapin (Ter) on the aconitine (Aco)- and carbachol (CCh)-induced action potential 
changes in single atrial cells. Action potentials were recorded in the current-clamp mode.  (A) Action 
potentials recorded during control period (open circle) and after 30 nM tertiapin (closed square). (B) 
Typical action potentials recorded during control period (open circle), after 3 µM aconitine (closed 
triangle) and after addition of 30 nM tertiapin (3 µM aconitine plus 30 nM tertiapin) (closed square). (C) 
Action potentials recorded during control period (open circle), after 3 nM carbachol (closed triangle) and 
after addition of 30 nM tertiapin (3 µM aconitine plus 30 nM tertiapin) (closed square).(D) Summarized 
data of action potential duration at 90% repolarization (APD90) before and after various drug alone or in 
combination. Left columns indicate APD90 values during control period and after 30 nM tertiapin alone 
(n=6). Middle columns indicate APD90 values during control period, after 3 µM aconitine alone and after 
addition of 30 nM tertiapin (3 µM aconitine plus 30 nM tertiapin)(n=7). Right columns indicate APD90 
values during control period, after 3 nM carbachol alone and after addition of 30 nM tertiapin (3 nM 
carbachol plus 30 nM tertiapin)(n=5). Values are expressed as mean ± S.E. Statistical significance was 
evaluated by ANOVA. 

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Figure 3.  Effects of aconitine and carbachol on the tertiapin-sensitive current in single atrial cells. The 
quasi-steady-state current was recorded in the voltage-clamp mode using the ramp-pulse protocol and I-V 
relationship was plotted. (A) Membrane currents recorded during control period (open circle) and after 30 
nM tertiapin alone (closed square). (B) Membrane currents during control period (open circle), after 3 µM 
aconitine (closed triangle), and after addition of 30 nM tertiapin to 3 µM aconitine (closed square). (C) 
Membrane currents during control period (open circle), after 3 nM carbachol (closed triangle), and after 
addition of 30 nM tertiapin to 3 nM carbachol (closed square). (D) Summarized data of the tertiapin (30 
nM)-sensitive current at 0 mV in he absence of drug (right, n=13) and presence of 3 µM aconitine (middle, 
n=10) or carbachol (right, n=5). Values are expressed as mean ± S.E. Statistical ignificance was evaluated by 
ANOVA. 

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Figure 4.  Effects of tertiapin on the membrane potential in the presence of 
aconitine in single atrial cells. Action potentials were recorded in the current-
clamp mode. (A) Typical action potential recorded in the absence of drugs 
(circle), 1.5 min after addition of 3 µM aconitine (triangle), 4.5 min after addition 
of 3 µM aconitine (induction of abnormal automaticity)(closed triangle) and 0.5 
min after addition of 30 nM tertiapin (square). (B) Summarized data of changes 
in the resting membrane potential when abnormal automaticity was induced by 3 
µM aconitine and after addition of 30 nM tertiapin.

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Figure 5.  Effect of tertiapin and pilsicainide on the aconitine-induced changes of excitation waves, 
recorded using two dimensional electrical mapping system, in isolated atrial preparations.  (A)(D)
(G), (B)(E)(H) and (C)(F)(I) were the mapping data obtained from the respective atrial preparation, 
respectively.  (A)(B)(C): The mapping data obtained in the control period after stabilization period.  
STIM:stimulation site.  (D)(E)(F): The mappings data obtained at 15 min after addition of 3 µM 
aconitine (just prior to addition of tertiapin or pilsicainide).  Aconitine induced the ectopic firing 
within 10-15 min. (G): The mapping data obtained 20 min after addition of 3 µM aconitine (without 
any drug treatment). (H):5 min after addition of 30 nM tertiapin to 3 µM aconitine. (I):5 min after 
addition of 10 µM pilsicainide to 3 µM aconitine. Arrows indicate the direction of excitation.

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Figure 6.  Effects on aconitine alone, addition of tertiapin and pilsicainide on conduction velocity 
calculated from mapping data. After introduction of 3 µM aconitine mapping data were obtained at 
15 min and 20 min in aconitine alone group . In tertiapin group and pilsicainide group, the 
mappings data were obtained at 15 min after application of 3 µM aconitine (just prior to addition of 
tertiapin or pilsicainide) and at 5 min after addition of tertiapin or pilsicainide to the aconitine-
containing solution. Values are expressed as mean ± S.E of 5 preparations for aconitine alone group, 
6 preparations for tertiapin group and 5 preparations for pilsicainide group. Statistical significance 
was evaluated by ANOVA. 
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